Company News
-
Oct 29, 2024Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK’s AREXVY
-
Jun 18, 2024Clover Announces Positive Preliminary PhaseⅠResults for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults
-
Apr 8, 2024Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
-
Dec 29, 2023Clover Announces Positive PhaseⅠResults for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)
-
Dec 13, 2023Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate
-
Nov 7, 2023Clover Completes BLA Submission for Seasonal Influenza Vaccine in Brazil
-
Sep 12, 2023Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China
-
Jul 11, 2023Clover Provides Updates on Business and R&D Pipeline Development
-
May 24, 2023Clover Expands Sales and Distribution Network for Upcoming Quadrivalent Seasonal Influenza Vaccine Launch in China
-
Mar 29, 2023Clover Announces Corporate Updates and Full Year 2022 Financial Results
-
Feb 20, 2023Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China
-
Feb 14, 2023Clover Launches COVID-19 Booster Vaccine in the People's Republic of China
-
Jan 16, 2023Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
-
Nov 30, 2022Clover's Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
-
Oct 9, 2022Clover Provides Update on 2022 Corporate Milestones
-
Sep 20, 2022Clover's COVID-19 Vaccine Candidate Receives European Union GMP Certificate
-
Sep 20, 2022Clover's Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated Vaccine
-
Sep 6, 2022Clover's COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine
-
Aug 30, 2022Clover's COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5
-
Aug 25, 2022Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine
